Navigation Links
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
Date:6/4/2008

matologic toxicities were seen. Hematologic toxicities included 29 percent grade 3/4 neutropenia, with 7 percent being grade 4, 46 percent grade 3 thrombocytopenia, and 18 percent grade 3 anemia.

For all patients (n=28), overall response and complete response rates were 57 percent and 46 percent, respectively. Median time to progression for these patients was 11 months and the two-year overall survival was estimated to be 76 percent. For rituximab-refractory follicular lymphoma patients (n=14), overall response and complete response rates were 86 percent and 64 percent, respectively. Median time to progression for this subset of patients was 14 months and the two-year overall survival was estimated to be 93 percent. Notably, responses to the MGd/Zevalin combination were seen within the first four weeks of treatment.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Novel Technology Breaks Through Cancer Pain
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
6. NIST team develops novel method for nanostructured polymer thin films
7. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
10. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
11. GenVault and the National Center for Forensic Science to Present Novel Technology for Room Temperature Storage of RNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... 23, 2013 VG Energy, an agricultural ... DAK Renewable Research to conduct field trials using ... Energy is a majority owned subsidiary of VG ... VG Energy,s exclusively licensed compound LipidMax selectively inhibits ... in plants, possessing a wide variety of applications ...
(Date:5/23/2013)... 2013 On April 19th the ... to search for the growing antibiotic resistant bacteria that ... a year long study were released late last month ... meats, over previous years. For those suffering from bacteria ... antibiotic resistant bacteria in food, may eventually help breed ...
(Date:5/23/2013)... May 23, 2013 Pressure BioSciences, Inc. (OTCQB: ... Company will host a teleconference to discuss its First ... update. The teleconference information is provided below: ... Daylight Time (EDT) Dial-in: (800) 875-3456 (U.S.); ... (Int,l) Passcode: VS22823 For those unable to ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 28 Stryker Corporation (NYSE: SYK ) learned today ... has returned an indictment charging Stryker Biotech LLC and certain ... conspiracy to defraud the U.S. Food and Drug Administration (FDA), ... FDA. The Company disclosed in March of this year that ...
... The Center for Business Intelligence (CBI), a division of Advanstar ... panel on Regulatory Risks, Compliance and Validation at ... coming up November 2 - 3, 2009 at the Doubletree ... CDRH Division of Bioresearch Monitoring of the FDA , ...
... MINNEAPOLIS, Oct. 28 Techne Corporation,s (Nasdaq: TECH ... 30, 2009 decreased 6.4% to $26.8 million or $.72 ... per diluted share for the quarter ended September 30, ... due to foreign currency fluctuations, decreased consolidated net sales ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 2Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 4Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 5Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 6
(Date:5/24/2013)... immune system to combat metastatic cancer , Cancer ... by the immune system. Stimulation of the immune system ... many factors that cause the immune system to ignore ... function to suppress the immune system response. In this ... researchers led by Ronald Levy at Stanford University found ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... What would be your response to a radiological incident? How ... take care of us? How do we even know if we ... addressed at the 42nd Midyear Topical Meeting of the Health Physics ... San Antonio, Texas at the Henry B. Gonzales Convention Center. The ...
... that certain marginalized groups including the mentally ill, ... and Latinos fare worse than others in the ... fatalities. Now, a new study ... also experience greater terrorism-related fears and make more behavioral ...
... Newark, Delaware became the first electric utility in the ... power for the local electric grid. The ... to store energy and improve grid reliability. University of ... With the City of Newark,s approval, the UD team ...
Cached Biology News:42nd Mid-year Topical Meeting of the Health Physics Society 2Disabled and other vulnerable groups more susceptible to terrorism fears 2City of Newark first in nation using cars to power grid 2
WNV Core Antibody...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: